CrossrefInfokarte
Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma
Drug Discoveries & Therapeutics · 2026-10-31 · 20 (5) · 400-402
DOI: 10.5582/ddt.2026.01067 ↗Abstract
Kein Abstract verfügbar.
EUVIMED